Kymera Investor Day Presentation Deck

KT-474 Phase 1 Trial Design Includes HV and Patients Double-blind, placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) trial Endpoints Three-part Phase 1 Design 1 SAD Portion Healthy Volunteers • 7 cohorts (up to 56 adult healthy subjects) 8 per cohort (6:2 randomization) Single dosing (starting dose 25 mg) 2 MAD Portion Healthy Volunteers 5 cohorts (up to 60 adult healthy subjects) 12 per cohort (9:3 randomization) • 14x daily doses (starting dose 25 mg) KYMERA ©2021 KYMERA THERAPEUTICS, INC. 3 MAD Portion Patient Cohort • 1 cohort (up to 20 AD and HS patients) Open-label 14x daily doses Primary Secondary/ Exploratory SAD & MAD Exploratory SAD & MAD Exploratory MAD Only KYMERA R&D DAY - December 16th, 2021 ● ● Pharmacokinetic measures (half-life, bioavailability) • IRAK4 knockdown in PBMC ● ● Safety & tolerability ● Ex vivo response of whole blood to TLR agonists (SAD & MAD) and IL-1B (MAD only) IRAK4 knockdown in skin biopsies Proinflammatory cytokine and chemokine levels in skin biopsies (Patients only) Plasma C-reactive protein (HV and Patients) and cytokine levels (Patients only) PAGE 26

View entire presentation